Compare · DXCM vs NVST
DXCM vs NVST
Side-by-side comparison of DexCom Inc. (DXCM) and Envista Holdings Corporation (NVST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NVST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 7.5x NVST ($3.76B).
- Over the past year, DXCM is down 14.9% and NVST is up 21.5% - NVST leads by 36.5 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 12 for NVST).
- DXCM has more recent analyst coverage (25 ratings vs 23 for NVST).
- Company
- DexCom Inc.
- Envista Holdings Corporation
- Price
- $72.84+0.38%
- $23.11+1.07%
- Market cap
- $28.11B
- $3.76B
- 1M return
- +20.73%
- -14.60%
- 1Y return
- -14.94%
- +21.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2019
- News (4w)
- 26
- 12
- Recent ratings
- 25
- 23
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest NVST
- Envista Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form SD filed by Envista Holdings Corporation
- Chief Executive Officer Keel Paul A covered exercise/tax liability with 12,811 shares, decreasing direct ownership by 3% to 371,574 units (SEC Form 4) to satisfy tax liability
- Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board
- Director Tsingos Christine A was granted 9,330 shares, increasing direct ownership by 18% to 59,930 units (SEC Form 4)
- Director Carruthers Wendy was granted 9,330 shares, increasing direct ownership by 18% to 59,940 units (SEC Form 4)
- Director Raskas Daniel was granted 9,330 shares, increasing direct ownership by 21% to 54,010 units (SEC Form 4)
- Director Huennekens R Scott was granted 12,585 shares, increasing direct ownership by 18% to 82,105 units (SEC Form 4)
- Director Pierce James Andrew was granted 9,330 shares, increasing direct ownership by 102% to 18,485 units (SEC Form 4)
- Director Gallahue Kieran was granted 9,330 shares, increasing direct ownership by 21% to 54,010 units (SEC Form 4)